Silco Pharmaceuticals Ltd.
DDSE:SILCOPHL15.00
BDT
+0.30
(+2.04%)
Silco Pharmaceuticals Ltd.
DSE:SILCOPHL
(Dhaka Stock Exchange)
Recent
price
15.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Silco Pharmaceuticals Limited is a Bangladesh-based pharmaceutical manufacturing company engaged in the development, formulation, production, marketing, and distribution of generic finished pharmaceutical products and human healthcare therapeutics. Founded in 1995 and headquartered in Sylhet, Bangladesh, the company operates manufacturing plants designed in compliance with current Good Manufacturing Practices (cGMP) to supply healthcare institutions, pharmacies, and medical practitioners nationwide. Its diversified product portfolio encompasses a broad spectrum of dosage forms and therapeutic categories, including solid oral dosage forms such as uncoated, film-coated, enteric-coated, and sustained-release tablets; hard gelatin capsules; liquid preparations comprising oral solutions, syrups, and pediatric suspensions; dry powder suspensions; topical preparations including dermatological creams, ointments, and gels; and oral nutritional and dietary formulations. These offerings serve key therapeutic classifications, including anti-infectives and broad-spectrum antibiotics; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs (NSAIDs); gastrointestinal agents, proton pump inhibitors, and antacids; cardiovascular, antihypertensive, and lipid-lowering therapies; antiallergics and antihistamines; respiratory medications, bronchodilators, and mucolytics; antidiabetic agents; and essential multivitamins, minerals, and hematinics. In recent operational developments, Silco Pharmaceuticals Limited has executed ongoing production expansion and modernization projects at its main Sylhet manufacturing complex, installing advanced high-speed packaging equipment and upgrading analytical quality control laboratories to scale domestic output. The company has simultaneously expanded its product pipeline through the introduction of newly formulated generic molecules targeting chronic diseases, enhanced its regional distribution logistics across Bangladesh, and strengthened regulatory compliance protocols to support prospective export registrations in semi-regulated international markets.